Insider Trading July 1, 2026 06:19 PM

Stitch Fix CPO Unloads $309K in Shares Under Pre-Arranged Plan

Anthony Bacos executes sell transactions while company navigates post-earnings guidance upgrade and AI platform expansion.

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
SFIX

Anthony Bacos, Stitch Fix’s Chief Product and Technology Officer, sold $309,663 worth of the company’s Class A Common Stock on June 29, 2026, under a Rule 10b5-1 trading plan established earlier in the year. The sale of 70,011 shares occurred at prices between $4.35 and $4.51, shortly after the company reported stronger-than-expected fiscal third-quarter results and raised its full-year guidance. Despite the positive operational updates, the stock has declined ~9% over the past week, trading at $4.01, while Mizuho maintains an Underperform rating with a $3.00 price target, citing rising costs.

Stitch Fix CPO Unloads $309K in Shares Under Pre-Arranged Plan
SFIX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Anthony Bacos sold $309,663 worth of SFIX shares on June 29, 2026, under a Rule 10b5-1 plan, while simultaneously acquiring 50,011 shares through option exercises valued at $124,043.
  • Stitch Fix reported fiscal Q3 2026 revenue of $340.3 million, beating estimates of $332.56 million, and raised full-year guidance, yet the stock has declined ~9% to $4.01 amid analyst concerns over rising costs.
  • The company is expanding its AI capabilities with the "See it on me" feature in Stitch Fix Vision and has restructured leadership by appointing Sree Sreedhararaj as Chief Product and Technology Officer.

Anthony Bacos, serving as the Chief Product and Technology Officer at Stitch Fix, Inc. (NASDAQ: SFIX), completed a transaction on June 29, 2026, that resulted in the sale of $309,663 worth of the company’s Class A Common Stock. The divestiture was conducted under the framework of a Rule 10b5-1 trading plan, which Bacos established on March 17, 2026. This pre-arranged structure dictates the timing and execution of the trades, removing direct market timing discretion from the executive at the point of sale.


On the execution date, Bacos disposed of exactly 70,011 shares. The transaction was not executed at a single price point but rather across a range of $4.35 to $4.51 per share. Detailed breakdown of the execution reveals two distinct tranches: 20,000 shares were sold at a weighted average price of $4.4225, while the remaining 50,011 shares were sold at a weighted average price of $4.4233. Following the sale, Bacos’s direct holding in Stitch Fix Class A Common Stock stands at 1,051,994 shares.


Concurrent with the sale, Bacos also engaged in a stock option exercise on the same day, acquiring 50,011 shares of Class A Common Stock with a total value of $124,043. This acquisition was structured through two distinct exercise price points: 11 shares were exercised at $3.99 per share, and 50,000 shares were exercised at $2.48 per share. The underlying options utilized for this acquisition featured various vesting schedules, indicating a phased approach to equity compensation.


The timing of these transactions follows Stitch Fix’s release of fiscal third-quarter 2026 results, which surpassed Wall Street consensus. The company reported an adjusted loss of $0.01 per share against expectations, while generating revenue of $340.3 million, significantly exceeding the forecasted $332.56 million. In conjunction with the earnings release, Stitch Fix upgraded its fiscal 2026 revenue and EBITDA guidance, signaling management confidence in the company’s forward trajectory.


Despite the positive operational metrics and guidance upgrade, the equity market has reacted with caution. The stock currently trades at $4.01, reflecting a decline of approximately 9% over the past week. This downward pressure is corroborated by Mizuho, which has reiterated an Underperform rating for Stitch Fix. The analyst firm maintains a $3.00 price target, explicitly citing rising costs as a primary concern for the company’s near-term financial health.


Operational developments accompany the financial updates, as Stitch Fix continues to pivot toward technology-driven personalization. The company recently expanded its AI style visualization platform, Stitch Fix Vision, by introducing a feature titled "See it on me." This functionality allows clients to generate personalized images of themselves wearing recommended outfits, aiming to enhance the Freestyle experience. Additionally, the company has appointed Sree Sreedhararaj as Chief Product and Technology Officer, consolidating oversight of technology, product, data science, security, and IT teams under a single leadership structure.


While the insider sale is executed under a pre-arranged plan, the divergence between management’s raised guidance and the stock’s recent performance, alongside analyst skepticism about cost structures, highlights the complex valuation environment for SFIX. Investors are weighing the company’s AI innovation and revenue beat against persistent margin pressures and a broader market sentiment that has driven the stock down ~9% in the past week.

Risks

  • Mizuho maintains an Underperform rating with a $3.00 price target, explicitly citing rising costs as a persistent headwind for Stitch Fix’s profitability.
  • The stock has experienced a ~9% decline over the past week, indicating negative market sentiment despite the company beating revenue estimates and raising guidance.
  • The divergence between management’s optimistic guidance and the stock’s downward trajectory suggests ongoing valuation uncertainty and potential skepticism from investors regarding the company’s cost management.

More from Insider Trading

Axsome Therapeutics CEO Executes $11.9 Million Stock Sale Under 10b5-1 Plan Jul 1, 2026 Westwood Holdings Director Emerita Susan Byrne Executes $247,812 in Stock Sales Jul 1, 2026 Insider Accumulation: Bradley Entities and Funds Acquire JCTC Shares Amid Profitability Pressures Jul 1, 2026 Core Scientific Legal Officer Executes Pre-Arranged Stock Sales Amid Market Volatility Jul 1, 2026 HRT Financial Accumulates Shuttle Pharmaceuticals Shares as Stock Trades Near Lows Jul 1, 2026